A pharmaceuticals giant has been left “disappointed” after its colorectal cancer treatment Recentin failed to meet its main goal in a clinical study.
AstraZeneca said the drug, otherwise known as cediranib, did not meet the primary endpoint in the study which compared it with rival treatment Avastin.
“While we recognised that challenging Avastin would be a high hurdle, it is still disappointing, despite evidence of clinical activity with Recentin, not to have met the primary endpoint in this study,” Alan Barge of Astra’s oncology division said.
The company will carry out a further two studies involving Recentin. The first will examine the impact of the drug combined with chemotherapy versus chemotherapy alone. The second will research the drug’s success as a treatment for tumours.
Results of a Phase III study with cediranib in treating recurrent glioblastoma are also expected in the first half of 2010. Exploratory evaluations of cediranib in other tumours are also ongoing.
Copyright Press Association 2010